Which of the following is a characteristic of SGAs compared to FGAs?

Second-generation antipsychotics (SGAs) are known for their effectiveness across a broader spectrum of symptoms compared to first-generation antipsychotics (FGAs). While FGAs primarily target positive symptoms of schizophrenia, such as hallucinations and delusions, SGAs also address negative symptoms, including apathy, lack of emotion, and social withdrawal, as well as cognitive deficits. This broader effectiveness is largely attributed to the unique pharmacological profiles of SGAs, which enhance serotonin receptor influence in addition to dopamine receptor antagonism.

In contrast, the other characteristics listed are not accurate representations of SGAs. They generally possess a lower risk of extrapyramidal symptoms (EPS) than FGAs, which are more commonly associated with these side effects due to their stronger dopamine blockade. SGAs also tend to have a higher risk of metabolic side effects, such as weight gain and diabetes, when compared to FGAs. Moreover, SGAs often offer once-daily dosing options or long-acting injectable formulations, making them more convenient for patients compared to some FGAs that may require more frequent dosing. This combination of factors highlights the clinical advantage of SGAs in treating a wider range of symptoms effectively.